Cytokinetics Inc. - CYTK STOCK NEWS

Cytokinetics (CYTK) announced it will report its Q1 results on May 4, 2022, at 4:00 PM ET, followed by a conference call at 4:30 PM ET. The call will cover operational and financial results, alongside future outlook. Investors can access the conference call via their website or by phone. An archived replay will be available from May 4 until May 18, 2022. Cytokinetics is focused on developing muscle-targeted therapies, including cardiac muscle activator omecamtiv mecarbil and next-generation cardiac myosin inhibitor aficamten, with ongoing Phase 3 clinical trials.

Cytokinetics (NASDAQ: CYTK) announces significant changes to its Board of Directors effective April 8, 2022. L. Patrick Gage, Ph.D., resigns as Chairman after over a decade, while John T. Henderson, M.B., Ch.B., steps into the role. Additionally, Robert A. Harrington, M.D., joins the Board, bringing extensive clinical trial experience. Dr. Henderson, a long-standing Board member, is set to guide the company during its transformation. Cytokinetics remains focused on developing innovative muscle-related therapies, including the potential commercialization of omecamtiv mecarbil for heart failure.

Cytokinetics announced that CEO Robert I. Blum will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 11:00 AM ET. The live webcast can be accessed on the company's website, with a replay available for 90 days post-event.

Cytokinetics is a late-stage biopharmaceutical company focused on muscle activators and inhibitors for diseases affecting muscle performance. Their lead drug, omecamtiv mecarbil, has shown positive Phase 3 trial results for heart failure, while aficamten is being evaluated for hypertrophic cardiomyopathy.

Cytokinetics announced findings from two major studies, METEORIC-HF and GALACTIC-HF, regarding omecamtiv mecarbil for heart failure treatment. METEORIC-HF showed no improvement in exercise capacity among HFrEF patients, with changes in peak oxygen uptake negligible compared to the placebo. Conversely, GALACTIC-HF data indicated a 19% reduction in healthcare costs per patient treated with omecamtiv mecarbil in a specific subgroup, alongside a reduction in heart failure events. The results affirm the drug's safety and impact on treatment costs in both inpatient and outpatient settings.

Cytokinetics announced positive results from Cohort 3 of the Phase 2 clinical trial REDWOOD-HCM for aficamten, a treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM). Patients receiving aficamten showed significant reductions in left ventricular outflow tract gradients, with resting gradients decreasing from 50 mmHg to 24 mmHg (p < 0.0001). Furthermore, 46% of patients experienced a complete hemodynamic response. Treatment was well tolerated with no serious adverse events noted. These findings support aficamten's inclusion in the ongoing Phase 3 trial, SEQUOIA-HCM.

Cytokinetics, Inc. (Nasdaq: CYTK) announced the granting of stock options for 165,600 shares to eighteen new employees as an inducement to employment on March 31, 2022. The options have an exercise price of $36.81 per share, equal to the closing stock price on that day, and will vest over four years. This initiative complies with Nasdaq Listing Rule 5635(c)(4). Cytokinetics focuses on developing innovative muscle activators and inhibitors for serious medical conditions, including heart failure and amyotrophic lateral sclerosis.

Cytokinetics announced four key presentations at the American College of Cardiology 71st Annual Scientific Session in Washington, D.C., from April 2-4, 2022. Highlights include full results from the METEORIC-HF Phase 3 clinical trial of omecamtiv mecarbil, focusing on patients with heart failure. The company will also present findings from REDWOOD-HCM, a Phase 2 trial for aficamten in hypertrophic cardiomyopathy. These insights could significantly impact treatment strategies for heart-related conditions.

Cytokinetics, Incorporated (Nasdaq: CYTK) announced that CEO Robert I. Blum will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 11:20 am ET and participate in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 11:45 am ET in Miami Beach. Interested parties can access live and archived webcasts of both events on Cytokinetics' website for 90 days post-event. The company is focused on developing muscle activators and inhibitors, with significant products in the pipeline, including omecamtiv mecarbil and aficamten.

Cytokinetics has announced the enrollment for Cohort 4 of its REDWOOD-HCM Phase 2 clinical trial, focusing on patients with non-obstructive hypertrophic cardiomyopathy (HCM). This cohort will investigate the safety and tolerability of aficamten, a next-generation cardiac myosin inhibitor. Approximately one-third of HCM patients face non-obstructive symptoms, with few treatment options available. Previous cohorts demonstrated significant efficacy in symptomatic obstructive HCM patients, paving the way for further trials in broader HCM populations.